Integer Holdings Corporation operates as a medical device contract development and manufacturing company in the United States, Costa Rica, Puerto Rico, Ireland, and internationally. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures. It also provides cardiac rhythm management products, including implantable pacemakers, implantable cardioverter defibrillators, insertable cardiac monitors, implantable cardiac pacing and defibrillation leads, and heart failure therapies; implanted medical devices, implanted leads, procedure accessories, and external devices; neuromodulation products, such as implantable spinal cord stimulators; and non-rechargeable batteries, feedthroughs, device enclosures, machined components, and lead components and sub-assemblies. In addition, the company offers rechargeable batteries and chargers; orthopedics, minimally invasive surgery, and general surgery devices; and portable medical devices, including patient monitoring, ventilators, portable defibrillators, portable ultrasound, and X-Ray machines. Furthermore, the company provides medical technologies; supplies medical stamped components, and shallow and deep draw casings and assemblies; and epicardial pacing leads. It serves multi-national original equipment manufacturers and affiliated subsidiaries in the cardiac rhythm management, neuromodulation, orthopedics, cardio and vascular, and advanced surgical and portable medical markets. The company provides its products under the Greatbatch Medical and the Lake Region Medical brands. The company was formerly known as Greatbatch, Inc. and changed its name to Integer Holdings Corporation in July 2016. Integer Holdings Corporation was founded in 1970 and is headquartered in Plano, Texas.
Future Prospects | Discover Integer's potential in the emerging pulsed field ablation market, positioning the company for significant growth in cardiac care technology |
Financial Outlook | Learn about Integer's focus on margin recovery and debt reduction, with analysts setting price targets around $139 and maintaining an "Overweight" rating |
Growth Strategies | Delve into Integer's ambitious organic growth targets, aiming to exceed market rates by 200 basis points through profitability and efficiency initiatives |
Market Leade | Explore Integer Holdings' strong position in medical device outsourcing, with a market cap of $4.71 billion and impressive 60.24% stock return over the past yea |

Metrics to compare | ITGR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipITGRPeersSector | |
|---|---|---|---|---|
P/E Ratio | 28.6x | 13.8x | −0.4x | |
PEG Ratio | −2.01 | 1.71 | 0.00 | |
Price / Book | 1.7x | 1.1x | 2.6x | |
Price / LTM Sales | 1.6x | 1.4x | 3.1x | |
Upside (Analyst Target) | 9.6% | 60.4% | 56.0% | |
Fair Value Upside | Unlock | 12.1% | 9.0% | Unlock |